Skip to main content

Advertisement

Articles

Page 15 of 15

  1. Alzheimer's disease (AD) is widely recognized as a serious public health problem and heavy financial burden. Currently, there is no treatment that can delay or stop the progressive brain damage in AD. Recently...

    Authors: Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley and Li-Ru Zhao

    Citation: Alzheimer's Research & Therapy 2011 3:8

    Content type: Research

    Published on:

  2. There are more than 36 million people in the US over the age of 65, and all of them are impacted by the cognitive decline and brain atrophy associated with normal aging and dementia-causing conditions like Alz...

    Authors: Neill R Graff-Radford

    Citation: Alzheimer's Research & Therapy 2011 3:6

    Content type: Review

    Published on:

  3. Levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) and Tau proteins change in Alzheimer's disease (AD). We tested if the relationships of these biomarkers with cognitive impairment are linear or non-linear.

    Authors: Jonathan H Williams, Gordon K Wilcock, Jeffrey Seeburger, Aimee Dallob, Omar Laterza, William Potter and A David Smith

    Citation: Alzheimer's Research & Therapy 2011 3:5

    Content type: Research

    Published on:

  4. Alzheimer disease (AD) is a devastating neurodegenerative disease affecting 1 in 68 in the population. An arbitrary cutoff 65 years as the age of onset to distinguish between early- and late-onset AD has been ...

    Authors: Kinga Szigeti and Rachelle S Doody

    Citation: Alzheimer's Research & Therapy 2011 3:4

    Content type: Review

    Published on:

  5. Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and mole...

    Authors: Randall J Bateman, Paul S Aisen, Bart De Strooper, Nick C Fox, Cynthia A Lemere, John M Ringman, Stephen Salloway, Reisa A Sperling, Manfred Windisch and Chengjie Xiong

    Citation: Alzheimer's Research & Therapy 2011 3:1

    Content type: Review

    Published on:

  6. Inhibition of gamma-secretase presents a direct target for lowering Aβ production in the brain as a therapy for Alzheimer's disease (AD). However, gamma-secretase is known to process multiple substrates in add...

    Authors: Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui…

    Citation: Alzheimer's Research & Therapy 2010 2:36

    Content type: Research

    Published on:

  7. While Alzheimer's disease researchers continue to debate the underlying cause(s) of the disease, most agree that a diverse, multi-target approach to treatment will be necessary. To this end, the Alzheimer's Dr...

    Authors: Linda H Lee, Diana W Shineman and Howard M Fillit

    Citation: Alzheimer's Research & Therapy 2010 2:33

    Content type: Meeting report

    Published on:

  8. In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-b...

    Authors: Henrik Zetterberg, Niklas Mattsson, Kaj Blennow and Bob Olsson

    Citation: Alzheimer's Research & Therapy 2010 2:32

    Content type: Review

    Published on:

  9. There is a great need for quick tests that identify treatment response in Alzheimer's disease (AD) to determine who benefits from the treatment. In this study, A Quick Test of cognitive speed (AQT) was compare...

    Authors: Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2010 2:29

    Content type: Research

    Published on:

  10. With the advent of advances in biomarker detection and neuropsychological measurement, prospects have improved for identifying and tracking the progression of Alzheimer's disease (AD) from its earliest stages ...

    Authors: Larry G Brooks and David A Loewenstein

    Citation: Alzheimer's Research & Therapy 2010 2:28

    Content type: Review

    Published on:

  11. Structural brain deficits have been repeatedly linked to body mass index and obesity, which itself is controlled by the effects of a number of independent genetic loci. One of the most consistently replicated ...

    Authors: Lars Bertram and Hauke Heekeren

    Citation: Alzheimers Res Ther 2010 2:27

    Content type: Commentary

    Published on:

  12. Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this s...

    Authors: Roy W Jones

    Citation: Alzheimer's Research & Therapy 2010 2:25

    Content type: Commentary

    Published on:

  13. Atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful biomarker of the stage and intensity of the neurodegenerative aspect of Alzheimer's disease (AD) pathology. In this review, we wil...

    Authors: Prashanthi Vemuri and Clifford R Jack Jr

    Citation: Alzheimer's Research & Therapy 2010 2:23

    Content type: Review

    Published on:

  14. The present review of Alzheimer's disease (AD) rating scales aims to outline the need for a new rating scale to be used in routine clinical practice for long-term medical care of AD patients. An ideal scale would...

    Authors: Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad and Frank Tennigkeit

    Citation: Alzheimer's Research & Therapy 2010 2:24

    Content type: Research

    Published on:

  15. Since the reformulation of the amyloid cascade hypothesis to focus on oligomeric aggregates of amyloid beta as the prime toxic species causing Alzheimer's disease, many researchers refocused on detecting a spe...

    Authors: Kerensa Broersen, Frederic Rousseau and Joost Schymkowitz

    Citation: Alzheimer's Research & Therapy 2010 2:12

    Content type: Review

    Published on:

  16. Recently, it has become clear that head trauma can lead to a progressive neurodegeneration known as chronic traumatic encephalopathy. Although the medical literature also implicates head trauma as a risk facto...

    Authors: Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski and Ann C McKee

    Citation: Alzheimer's Research & Therapy 2010 2:18

    Content type: Commentary

    Published on:

  17. Recent advances in biomarkers for Alzheimer's disease (AD) now allow the visualization of one of the hallmark pathologies of AD in vivo, and combination biomarker profiles can now approximate the diagnostic accur...

    Authors: Reisa Sperling and Keith Johnson

    Citation: Alzheimer's Research & Therapy 2010 2:17

    Content type: Viewpoint

    Published on:

  18. Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tiss...

    Authors: Erik Stomrud, Maria Björkqvist, Sabina Janciauskiene, Lennart Minthon and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2010 2:20

    Content type: Research

    Published on:

  19. Evidence from clinical samples and geographically limited population studies suggests that vascular health, diabetes and apolipoprotein ε4 (APOE) are associated with dementia.

    Authors: David J Llewellyn, Iain A Lang, Fiona E Matthews, Brenda L Plassman, Mary AM Rogers, Lewis B Morgenstern, Gwenith G Fisher, Mohammed U Kabeto and Kenneth M Langa

    Citation: Alzheimer's Research & Therapy 2010 2:19

    Content type: Research

    Published on:

  20. The amyloid hypothesis provides a basis for the development of new therapeutic strategies in Alzheimer's disease. Two large trials have recently been published. The first is a phase 2 study of passive immunoth...

    Authors: Niels D Prins, Pieter Jelle Visser and Philip Scheltens

    Citation: Alzheimer's Research & Therapy 2010 2:5

    Content type: Commentary

    Published on:

  21. LY450139 (semagacestat) inhibits γ-secretase, a key enzyme for generation of amyloid β (Aβ), the peptide deposited in plaques in Alzheimer disease (AD). Previous data have shown that LY450139 lowers plasma Aβ,...

    Authors: Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2010 2:7

    Content type: Research

    Published on:

  22. Since the 1990s, the genetics of Alzheimer disease (AD) has been an active area of research. The identification of deterministic mutations in the APP, PSEN1, and PSEN2 genes responsible for early-onset autosomal ...

    Authors: Nilüfer Ertekin-Taner

    Citation: Alzheimer's Research & Therapy 2010 2:3

    Content type: Review

    Published on:

  23. Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate t...

    Authors: Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby and Wenyaw Chan

    Citation: Alzheimer's Research & Therapy 2010 2:2

    Content type: Research

    Published on:

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2010 2:14

  24. There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease...

    Authors: Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui and Rachelle S Doody

    Citation: Alzheimers Res Ther 2009 1:7

    Content type: Research

    Published on:

  25. Amyloid is deposited in the walls of arteries and capillaries as cerebral amyloid angiopathy (CAA) in the brains of older individuals and of those with Alzheimer disease (AD). CAA in AD reflects an age-related...

    Authors: Roy O Weller, Stephen D Preston, Malavika Subash and Roxana O Carare

    Citation: Alzheimer's Research & Therapy 2009 1:6

    Content type: Review

    Published on:

  26. Identifying the causes of dementia is important in the search for effective preventative and treatment strategies. The concept of mild cognitive impairment (MCI), as prodromal dementia, has been useful but rem...

    Authors: Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil and Carol Brayne

    Citation: Alzheimers Res Ther 2009 1:4

    Content type: Review

    Published on: